The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus ...

J&J is developing a second Taris-derived candidate called TAR-210, an intravesical formulation of J&J's FGFR kinase inhibitor Balversa (erdafitinib), and has predicted that peak sales of the two ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on Wednesday, April 2nd, IPO Scoop reports. The company plans to issue 2,700,000 shares at $7.50-$8.50 per share. The ...

Discover how AI-based assays offer a promising approach to tailor treatment for high-risk non-muscle-invasive bladder cancer.

Peter Clark presented results from the SunRISe-1 study at SESAUA 2025, evaluating TAR-200, an intravesical sustained-release gemcitabine system, in BCG-unresponsive high-risk non-muscle invasive ...

编者按： ...

Professors Rik Bryan and Nicholas James explain how an image-directed pathway for muscle-invasive bladder cancer improves ...

After hours: March 19 at 7:57:20 PM EDT Loading Chart for AGEN ...

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD. The pCR was 37.3% (95% ...

After hours: March 17 at 4:05:13 PM EDT Loading Chart for URGN ...

Following after in J&J's Taris-derived pipeline is TAR-210, an intravesical formulation of J&J's FGFR kinase inhibitor Balversa (erdafitinib), which started the phase 3 MoonRISe-1 trial in ...